Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-Adjuvanted vs Non-Adjuvanted H1N1 Vaccine in Chronic Disease
NCT01032395Phase 3Completed
- Sponsor
- Chiltern International
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in H1N1 influenza (H1N1) (4 arms), sponsored by Chiltern International. Primary endpoints: Geometric Mean HI Titer by Visit at Day 403, Geometric Mean Ratio by Visit and 5 more. Started Mar 2010; status: completed.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
H1N1 influenza (H1N1)
Beyond the preview
Go deeper on NCT01032395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032395.